OBJECTIVES:Habituation and adverse withdrawal reactions after prolonged medication with benzodiazepine (BZ) hypnotics are believed to play a role in dose escalation and the development of dependence. METHODS: In the current sleep EEG study in 43 healthy male subjects, the known property of BZ- and similar hypnotics to change the NREM sleep EEG spectrum is utilized for a detailed quantitative analysis across 4 weeks of continuous medication and a subsequent two-week withdrawal period. The BZ hypnotic triazolam and the non-BZ hypnotics zopiclone and zolpidem, differing in pharmacological properties and reported adverse effects, were examined in parallel to a placebo group. RESULTS: Reliably occurring spectral effects in the sleep stage 2 EEG were found in the 3 frequency bands 0.8-5 Hz, 5-10 Hz and 10-15 Hz. All 3 hypnotics showed the typical 'benzodiazepine signature', a 10-15 Hz increase and lower-frequency (<10 Hz) suppression relative to the preceding drug-free night. However, these effects developed differently across the first medication night, across the 4 medication weeks and after withdrawal: While the 5-10 Hz effect covaried with the blood presence of the drugs as estimated from the known plasma half-lifes, showed habituation and a rebound after withdrawal, the 10-15 Hz power increased across medication days and showed no rebound. Effects in the 0.8-5 Hz band in the first medication night correlated with the decrease of sleep efficiency at later withdrawal for triazolam and zolpidem.
RCT Entities:
OBJECTIVES: Habituation and adverse withdrawal reactions after prolonged medication with benzodiazepine (BZ) hypnotics are believed to play a role in dose escalation and the development of dependence. METHODS: In the current sleep EEG study in 43 healthy male subjects, the known property of BZ- and similar hypnotics to change the NREM sleep EEG spectrum is utilized for a detailed quantitative analysis across 4 weeks of continuous medication and a subsequent two-week withdrawal period. The BZ hypnotic triazolam and the non-BZ hypnotics zopiclone and zolpidem, differing in pharmacological properties and reported adverse effects, were examined in parallel to a placebo group. RESULTS: Reliably occurring spectral effects in the sleep stage 2 EEG were found in the 3 frequency bands 0.8-5 Hz, 5-10 Hz and 10-15 Hz. All 3 hypnotics showed the typical 'benzodiazepine signature', a 10-15 Hz increase and lower-frequency (<10 Hz) suppression relative to the preceding drug-free night. However, these effects developed differently across the first medication night, across the 4 medication weeks and after withdrawal: While the 5-10 Hz effect covaried with the blood presence of the drugs as estimated from the known plasma half-lifes, showed habituation and a rebound after withdrawal, the 10-15 Hz power increased across medication days and showed no rebound. Effects in the 0.8-5 Hz band in the first medication night correlated with the decrease of sleep efficiency at later withdrawal for triazolam and zolpidem.
Authors: Evan D Chinoy; Danielle J Frey; Daniel N Kaslovsky; Francois G Meyer; Kenneth P Wright Journal: Sleep Med Date: 2014-05-23 Impact factor: 3.492
Authors: Elisabeth Hertenstein; Agata Gabryelska; Kai Spiegelhalder; Christoph Nissen; Anna F Johann; Roza Umarova; Dieter Riemann; Chiara Baglioni; Bernd Feige Journal: J Clin Sleep Med Date: 2018-04-15 Impact factor: 4.062
Authors: Stephanie C Licata; Lisa D Nickerson; Steven B Lowen; George H Trksak; Robert R Maclean; Scott E Lukas Journal: Neuroimage Date: 2013-01-05 Impact factor: 6.556
Authors: Fiona C Baker; Stephanie A Sassoon; Tracey Kahan; Latha Palaniappan; Christian L Nicholas; John Trinder; Ian M Colrain Journal: J Sleep Res Date: 2012-03-14 Impact factor: 3.981
Authors: Steven V Fox; Anthony L Gotter; Spencer J Tye; Susan L Garson; Alan T Savitz; Jason M Uslaner; Joseph I Brunner; Pamela L Tannenbaum; Terrence P McDonald; Robert Hodgson; Lihang Yao; Mark R Bowlby; Scott D Kuduk; Paul J Coleman; Richard Hargreaves; Christopher J Winrow; John J Renger Journal: Neuropsychopharmacology Date: 2013-05-31 Impact factor: 7.853